SEARCH

SEARCH BY CITATION

References

  • 1
    Assaf C, Gellrich S, Steinhoff M et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges 2007; 5: 6628.
  • 2
    Terras S, Moritz RKC, Ditschkowski M et al. Allogeneic Haematopoietic Stem Cell Transplantation in a Patient with Cutaneous γ/δ-T-cell Lymphoma. Acta Derm Venereol 2013; 93: 3601.
  • 3
    Schlaak M, Kurschat P, Shimabukuro-Vornhagen A et al. ­Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after ­allogeneic stem cell transplantation. Transpl Immunol 2011; 25: 1636.
  • 4
    Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 8258.
  • 5
    Kim YH, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer. Blood 2007; 110: 47984.
  • 6
    Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of ­Cancer. Blood 2007; 110: 171322.
  • 7
    Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American J Clin Oncol 1982; 5: 64955.
  • 8
    Schlaak M, Pickenhain J, Theurich S et al. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database of Systematic Reviews (Online) 2012; 1: CD008908.
  • 9
    Duarte R, Canals C, Onida F et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 44929.
  • 10
    Delioukina M, Zain J, Palmer JM et al. Reduced-intensity ­allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012; 47: 6572.
  • 11
    Jacobsen ED, Kim HT, Ho VT et al. A large single-center ­experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011; 22: 160813.
  • 12
    Duvic M, Donato M, Dabaja B et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 2010; 28: 236572.
  • 13
    Paralkar VR, Nasta SD, Morrissey K et al. Allogeneic ­hematopoietic SCT for primary cutaneous T cell lymphomas. Bone Marrow Transplant 2012; 47: 9405
  • 14
    Wu PA, Kim YH, Lavori PW et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant 2009; 15: 98290.
  • 15
    Gratwohl A, Stern M, Brand R et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 471526.
  • 16
    Bertz H. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 13: 1359.
  • 17
    d'Amore F, Relander T, Lauritzsen GF et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 30939.
  • 18
    Reimer P, Rüdiger T, Geissinger E et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 10613.
  • 19
    Schlaak M, Theurich S, Pickenhain J et al. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. Crit Rev Oncol Hematol 2013; 1: 213.
  • 20
    Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 106873.
  • 21
    Le Gouill S, Milpied N, Buzyn A et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008; 26: 226471.
  • 22
    Hamadani M, Awan FT, Elder P et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 2008; 14: 4803.
  • 23
    Willemze R, Jaffe E, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 376885.